SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (3016)10/4/2017 3:21:42 PM
From: DewDiligence_on_SI  Read Replies (1) | Respond to of 3027
 
Although a 40mg launch is technically "at risk," TEVA's remaining patents on 40mg Copaxone will almost certainly be found unenforceable due to double-patenting/obviousness, so MYL is not incurring much risk by launching immediately.

There is no equivocation in MYL's PR about launching immediately—only about the 180-day exclusivity.